A phase II, randomized, open-label study evaluating the antitumor activity of MEDI-522, a humanized monoclonal antibody directed against the human alpha v beta 3 (avb3) integrin, ± dacarbazine (DTIC) in patients with metastatic melanoma (MM)
Year: 2005
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: P. Hersey, J. Sosman, S. O’Day, J. Richards, A. Bedikian, R. Gonzalez, W. Sharfman, R. Weber, T. Logan, J. M. Kirkwood
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2297929500